Airwheel Extends Smart Rideable Carry-On Hand Scooter Ai Wheel Robot 20inch Cabin Luxury Suitcase Momentum at the 140th Canton Fair 
MicroVision Begins Commercial Production of MOVIA(TM) Pro for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge 
ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease 
New Global Initiative Seeks to Modernize Health Workforce Mobility 
P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual…
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual…
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the…
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the…
Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR…
Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR…
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007…
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007…